Appointment of Nominated Adviser and Broker

Verona Pharma plc ("Verona Pharma" or the "Company") Appointment of Nominated Adviser and Broker 6 August 2014, Cardiff - Verona Pharma plc (AIM: VRP), the drug developmentcompany focused on first-in-class medicines to treat respiratory diseases, hasappointed N+1 Singer Advisory LLP ("N+1 Singer") as its Nominated Adviser andBroker with immediate effect. -Ends- For further information please contact: Verona Pharma plc Tel: +44 (0) 20 7863 3300Jan-Anders Karlsson, CEO N+1 Singer Tel: +44 (0)20 7496 3000Aubrey Powell / Jen Boorer FTI Consulting Tel: +44 (0)20 3727 1000Julia Phillips / Simon Conway Notes to Editors About Verona Pharma plc Verona Pharma is developing first-in-class drugs to treat respiratory disease,such as COPD and asthma. The Company currently has two drug programmes, one ofwhich is in Phase II trials for two diseases. The lead programme, RPL554, is an innovative dual phosphodiesterase (PDE) 3 and4 inhibitor with both bronchodilator and anti-inflammatory properties. In itssecond programme, Verona Pharma is investigating novel anti-inflammatorymolecules, called NAIPs, for a wide range of respiratory and inflammatorydiseases. About RPL554 for the treatment of COPD and Asthma Verona's lead drug, RPL554, is a dual phosphodiesterase (PDE) 3 and 4 inhibitorbeing developed as a novel treatment for chronic obstructive airways diseasesuch as COPD and asthma with bronchodilator and anti-inflammatory effects. Botheffects are essential to improve symptoms in patients with COPD or asthma.RPL554 is currently in Phase II for both diseases. COPD is a chronic lung disease with significant unmet need for which currenttreatment is far from optimal, as it often has unwanted side-effects and/orlimited effectiveness. COPD is most commonly characterised by fixed airflowobstruction and chronic airways inflammation resulting from exposure toirritants like tobacco smoke. Asthma, which remains one of the most commonchronic diseases in the world, is characterised by recurrent breathing problemsand symptoms such as breathlessness, wheezing, chest tightness, and coughing.The combined market for COPD and asthma drugs is currently estimated to beGBP20 billion (source: visiongain).